AstraZeneca strongly believes that interactions with HCPs/HCOs positively influence the quality of patient treatment and the value of medical research.

To provide patients with optimal treatment options, HCPs need to stay informed about the latest developments with current and potential new medicines. The pharmaceutical industry has a duty to provide this information.

HCPs in turn provide the industry with insights into how to improve medicines by feeding back on how they work in real world settings.

We also recognize that patients expect transparency around these relationships to feel confident that HCPs are impartial and always recommend the most appropriate the most appropriate treatment options.

We believe that regulations such as US Open Payments, the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure code, and others across the globe, which require companies to disclose payments and transfers of value made to HCPs and HCOs, will provide greater transparency around these already well-regulated relationships.

The payments and transfers of value disclosed here were made for activities such as providing professional advice about how medicines are used in practice, sharing professional expertise at medical education meetings, taking part in advisory boards, research and educational grants.